questionsmedicales.fr
Maladies cardiovasculaires
Maladies vasculaires
Embolie et thrombose
Thrombose
Thrombose veineuse
Syndrome de Budd-Chiari
Syndrome de Budd-Chiari : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Syndrome de Budd-Chiari
Échographie
Imagerie par résonance magnétique
Tests sanguins
Fonction hépatique
Coagulation
Ascite
Douleur abdominale
Hypertrophie hépatique
Échographie Doppler
Flux sanguin
Obstruction veineuse
Biopsie hépatique
Lésions hépatiques
Diagnostic différentiel
Symptômes
5
Douleur abdominale
Syndrome de Budd-Chiari
Hépatomégalie
Ascite
Hypertension portale
Cavité abdominale
Jaunisse
Bilirubine
Syndrome de Budd-Chiari
Asymptomatique
Syndrome de Budd-Chiari
Forme chronique
Prévention
5
Prévention
Troubles de la coagulation
Obésité
Anticoagulants
Prévention
Thromboses
Habitudes de vie
Alimentation équilibrée
Exercice
Vaccination
Hépatite
Complications hépatiques
Surveillance
Maladies hépatiques
Troubles de la coagulation
Traitements
5
Anticoagulants
Transplantation hépatique
Procédures endovasculaires
Anticoagulants
Thrombose veineuse
Complications
Procédure endovasculaire
Angioplastie
Stenting
Transplantation hépatique
Insuffisance hépatique
Complications
Traitements symptomatiques
Diurétiques
Ascite
Complications
5
Complications
Insuffisance hépatique
Hypertension portale
Insuffisance hépatique
Syndrome de Budd-Chiari
Complications
Hypertension portale
Veine porte
Obstruction
Complications à long terme
Cirrhose
Syndrome de Budd-Chiari
Prévention
Traitement précoce
Surveillance
Facteurs de risque
5
Facteurs de risque
Troubles de la coagulation
Obésité
Obésité
Syndrome de Budd-Chiari
Facteurs de risque
Maladies hépatiques
Cirrhose
Syndrome de Budd-Chiari
Contraceptifs oraux
Thrombose
Facteurs de risque
Tabagisme
Problèmes vasculaires
Thrombose
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Syndrome de Budd-Chiari : Questions médicales les plus fréquentes",
"headline": "Syndrome de Budd-Chiari : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Syndrome de Budd-Chiari : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-11",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Syndrome de Budd-Chiari"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Thrombose veineuse",
"url": "https://questionsmedicales.fr/mesh/D020246",
"about": {
"@type": "MedicalCondition",
"name": "Thrombose veineuse",
"code": {
"@type": "MedicalCode",
"code": "D020246",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C14.907.355.830.925"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Syndrome de Budd-Chiari",
"alternateName": "Budd-Chiari Syndrome",
"code": {
"@type": "MedicalCode",
"code": "D006502",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None Shalimar",
"url": "https://questionsmedicales.fr/author/None%20Shalimar",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India."
}
},
{
"@type": "Person",
"name": "Akash Shukla",
"url": "https://questionsmedicales.fr/author/Akash%20Shukla",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, 400012, India."
}
},
{
"@type": "Person",
"name": "Joseph J Alukal",
"url": "https://questionsmedicales.fr/author/Joseph%20J%20Alukal",
"affiliation": {
"@type": "Organization",
"name": "Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Talan Zhang",
"url": "https://questionsmedicales.fr/author/Talan%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Paul J Thuluvath",
"url": "https://questionsmedicales.fr/author/Paul%20J%20Thuluvath",
"affiliation": {
"@type": "Organization",
"name": "Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Ginsenoside Rg5 Sensitizes Paclitaxel-Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel-And Enhances the Anticancer Effect of Paclitaxel.",
"datePublished": "2022-06-24",
"url": "https://questionsmedicales.fr/article/35885925",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes13071142"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.",
"datePublished": "2023-09-17",
"url": "https://questionsmedicales.fr/article/37717927",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nano.2023.102707"
}
},
{
"@type": "ScholarlyArticle",
"name": "Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer.",
"datePublished": "2022-10-01",
"url": "https://questionsmedicales.fr/article/36231056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells11193094"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.",
"datePublished": "2023-02-14",
"url": "https://questionsmedicales.fr/article/36788648",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1759-7714.14795"
}
},
{
"@type": "ScholarlyArticle",
"name": "Paclitaxel extravasation treated with systemic corticosteroids.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/35906023",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ced.15348"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies cardiovasculaires",
"item": "https://questionsmedicales.fr/mesh/D002318"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies vasculaires",
"item": "https://questionsmedicales.fr/mesh/D014652"
},
{
"@type": "ListItem",
"position": 4,
"name": "Embolie et thrombose",
"item": "https://questionsmedicales.fr/mesh/D016769"
},
{
"@type": "ListItem",
"position": 5,
"name": "Thrombose",
"item": "https://questionsmedicales.fr/mesh/D013927"
},
{
"@type": "ListItem",
"position": 6,
"name": "Thrombose veineuse",
"item": "https://questionsmedicales.fr/mesh/D020246"
},
{
"@type": "ListItem",
"position": 7,
"name": "Syndrome de Budd-Chiari",
"item": "https://questionsmedicales.fr/mesh/D006502"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Syndrome de Budd-Chiari - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Syndrome de Budd-Chiari",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Syndrome de Budd-Chiari",
"description": "Comment diagnostiquer le syndrome de Budd-Chiari ?\nQuels tests sanguins sont utiles ?\nQuels signes cliniques indiquent ce syndrome ?\nL'échographie Doppler est-elle utile ?\nQuand envisager une biopsie hépatique ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Paclitaxel#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Syndrome de Budd-Chiari",
"description": "Quels sont les symptômes courants ?\nLa douleur abdominale est-elle fréquente ?\nQu'est-ce que l'ascite ?\nLa jaunisse est-elle un symptôme ?\nPeut-on avoir des symptômes asymptomatiques ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Paclitaxel#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Syndrome de Budd-Chiari",
"description": "Comment prévenir le syndrome de Budd-Chiari ?\nLes anticoagulants peuvent-ils prévenir ce syndrome ?\nQuelles habitudes de vie adopter ?\nLes vaccinations sont-elles importantes ?\nFaut-il surveiller les maladies hépatiques ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Paclitaxel#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Syndrome de Budd-Chiari",
"description": "Quels traitements sont disponibles ?\nQuand utiliser des anticoagulants ?\nQu'est-ce qu'une procédure endovasculaire ?\nQuand envisager une transplantation hépatique ?\nY a-t-il des traitements symptomatiques ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Paclitaxel#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Syndrome de Budd-Chiari",
"description": "Quelles sont les complications possibles ?\nL'insuffisance hépatique est-elle fréquente ?\nQu'est-ce que l'hypertension portale ?\nPeut-on avoir des complications à long terme ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Paclitaxel#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Syndrome de Budd-Chiari",
"description": "Quels sont les principaux facteurs de risque ?\nL'obésité augmente-t-elle le risque ?\nLes maladies hépatiques sont-elles un risque ?\nLes contraceptifs oraux sont-ils un facteur ?\nLe tabagisme influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Paclitaxel#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer le syndrome de Budd-Chiari ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'échographie, l'IRM et des tests sanguins pour évaluer la fonction hépatique."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les marqueurs de la fonction hépatique et les tests de coagulation."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent ce syndrome ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent l'ascite, la douleur abdominale et l'hypertrophie du foie."
}
},
{
"@type": "Question",
"name": "L'échographie Doppler est-elle utile ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet d'évaluer le flux sanguin dans les veines hépatiques et de détecter des obstructions."
}
},
{
"@type": "Question",
"name": "Quand envisager une biopsie hépatique ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie peut être envisagée si le diagnostic est incertain ou pour évaluer des lésions hépatiques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, douleur abdominale, jaunisse et ascite."
}
},
{
"@type": "Question",
"name": "La douleur abdominale est-elle fréquente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur abdominale est un symptôme fréquent, souvent localisée dans la partie supérieure droite."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que l'ascite ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'ascite est l'accumulation de liquide dans la cavité abdominale, souvent causée par une hypertension portale."
}
},
{
"@type": "Question",
"name": "La jaunisse est-elle un symptôme ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la jaunisse, due à une accumulation de bilirubine, est un symptôme courant du syndrome."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes asymptomatiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent être asymptomatiques, surtout dans les formes chroniques."
}
},
{
"@type": "Question",
"name": "Comment prévenir le syndrome de Budd-Chiari ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut la gestion des facteurs de risque comme les troubles de la coagulation et l'obésité."
}
},
{
"@type": "Question",
"name": "Les anticoagulants peuvent-ils prévenir ce syndrome ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anticoagulants peuvent prévenir les thromboses chez les patients à risque."
}
},
{
"@type": "Question",
"name": "Quelles habitudes de vie adopter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter une alimentation équilibrée, faire de l'exercice et éviter le tabac sont bénéfiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, se faire vacciner contre l'hépatite peut réduire le risque de complications hépatiques."
}
},
{
"@type": "Question",
"name": "Faut-il surveiller les maladies hépatiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, surveiller les maladies hépatiques et les troubles de la coagulation est crucial pour la prévention."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des anticoagulants, des procédures endovasculaires et, dans certains cas, une transplantation hépatique."
}
},
{
"@type": "Question",
"name": "Quand utiliser des anticoagulants ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticoagulants sont utilisés pour traiter les thromboses veineuses hépatiques et prévenir les complications."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une procédure endovasculaire ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une intervention pour débloquer les veines hépatiques, souvent par angioplastie ou stenting."
}
},
{
"@type": "Question",
"name": "Quand envisager une transplantation hépatique ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La transplantation est envisagée en cas d'insuffisance hépatique sévère ou de complications irréversibles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements symptomatiques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements symptomatiques comme les diurétiques peuvent aider à gérer l'ascite."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance hépatique, la thrombose et l'hypertension portale."
}
},
{
"@type": "Question",
"name": "L'insuffisance hépatique est-elle fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'insuffisance hépatique est une complication grave pouvant survenir dans ce syndrome."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que l'hypertension portale ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension portale est une augmentation de la pression dans la veine porte, causée par l'obstruction."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme comme la cirrhose peuvent se développer si non traitées."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un traitement précoce et une surveillance régulière."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent les troubles de la coagulation, l'obésité, et certaines maladies hépatiques."
}
},
{
"@type": "Question",
"name": "L'obésité augmente-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est un facteur de risque connu pour le syndrome de Budd-Chiari."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques sont-elles un risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies hépatiques, comme la cirrhose, augmentent le risque de ce syndrome."
}
},
{
"@type": "Question",
"name": "Les contraceptifs oraux sont-ils un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation prolongée de contraceptifs oraux peut augmenter le risque de thrombose."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut contribuer à des problèmes vasculaires, augmentant le risque de thrombose."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 06/04/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Publications dans "Syndrome de Budd-Chiari" :
4 publications dans cette catégorie
Affiliations :
Department of Gastroenterology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, 400012, India.
Publications dans "Syndrome de Budd-Chiari" :
3 publications dans cette catégorie
Affiliations :
Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA.
Publications dans "Syndrome de Budd-Chiari" :
3 publications dans cette catégorie
Affiliations :
Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA.
Publications dans "Syndrome de Budd-Chiari" :
3 publications dans cette catégorie
Affiliations :
Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Publications dans "Syndrome de Budd-Chiari" :
3 publications dans cette catégorie
Affiliations :
Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India.
Publications dans "Syndrome de Budd-Chiari" :
3 publications dans cette catégorie
Affiliations :
Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110 029, India.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
Department of Interventional Radiology, The Affiliated Hospital of XuZhou Medical University, Province Jiangsu, PR China.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China.
Department of Life Sciences and Biopharmaceutis, Shenyang Pharmaceutical University, Shenyang, China.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
Department of Radiology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, 400012, India.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110 029, India.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801507, India.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi 110029, Delhi, India.
Publications dans "Syndrome de Budd-Chiari" :
2 publications dans cette catégorie
Affiliations :
Department of Gastroenterology, Seth G S Medical College and KEM Hospital, Parel, Mumbai, 400012, India.
Publications dans "Syndrome de Budd-Chiari" :
1 publication dans cette catégorie
Affiliations :
Department of Interventional Radiology, The Affiliated Hospital of XuZhou Medical University, Province Jiangsu, PR China.
Publications dans "Syndrome de Budd-Chiari" :
1 publication dans cette catégorie
Affiliations :
Department of Interventional Radiology, The Affiliated Hospital of XuZhou Medical University, Province Jiangsu, PR China.
Publications dans "Syndrome de Budd-Chiari" :
1 publication dans cette catégorie
Affiliations :
Department of Interventional Radiology, The Affiliated Hospital of XuZhou Medical University, Province Jiangsu, PR China.
Publications dans "Syndrome de Budd-Chiari" :
In cervical cancer chemotherapy, paclitaxel (PTX) chemoresistance has become a major difficulty, and it also affects the survival rate of numerous tumor patients. Thus, for the reversal of chemoresist...
There are four kinds of taxanes: solvent-based paclitaxel (Sb-P), liposomal paclitaxel (Lps-P), nanoparticle albumin-bound paclitaxel (Nab-P), and docetaxel. This study aims to retrospectively evaluat...
Patients who were diagnosed with breast cancer and had received integral NST from August 2013 to April 2022 were enrolled. The efficacy was divided into total pathological complete response (total-pCR...
The choice of taxane was an independent risk factor for total-pCR and breast-pCR rates. The highest total-pCR and breast-pCR rates were found in the Nab-P group. The difference was not significant amo...
Nab-P significantly improved the total-pCR and breast-pCR rates. It should be the first choice among taxanes in NST for breast cancer....
Paclitaxel (PTX) is one of the most efficient drugs for late-stage non-small cell lung cancer (NSCLC) patients. However, most patients gradually develop resistance to PTX with long-term treatments. Th...
This study aimed to compare the feasibility of nab-paclitaxel plus platinum-based chemotherapy (nabTP) versus paclitaxel plus platinum-based chemotherapy (TP) with immune checkpoint inhibitors (ICIs) ...
Between April 2019 and March 2022, we identified ESCC patients who received neoadjuvant immunotherapy with both nabTP (n = 213) and TP (n = 98) at our institution and Henan Cancer Hospital. The patien...
All patients underwent esophagectomy with R0 resection. A statistically significant increase in the risk of developing major pulmonary (odds ratio [OR], 1.182; 95% confidence interval [CI]: 0.530-2.63...
It appears to be feasible to add immunotherapy to nabTP regimen for locally advanced ESCC. Compared with TP, nabTP plus ICIs can achieve a better pCR rate in ESCC....
Chemotherapy extravasation is a rare but severe cutaneous complication associated with administration of intravenous chemotherapy. Extravasation causes serious disability and diminishes the quality of...
Hypothesis The study aimed to use molecular hybridization of a cationic lipid with a known pharmacophore to produce a bifunctional lipid having a cationic charge to enhance fusion with the cancer cell...
Apatinib, an oral antiangiogenic drug, exerts potential anti-tumour effects on platinum-resistant recurrent ovarian cancer (PROC). This study intended to evaluate the efficacy and safety of apatinib p...
This retrospective cohort study reviewed 70 PROC patients who received apatinib plus paclitaxel (apatinib plus paclitaxel group) (N = 32) or paclitaxel monotherapy (paclitaxel monotherapy group) (N = ...
Disease control rate was elevated (84.4% vs. 60.5%, P = 0.028), whereas objective response rate only disclosed an increasing trend (lacked statistical significance) (37.5% vs. 18.4%, P = 0.074) in apa...
Apatinib plus paclitaxel exhibits better efficacy and acceptable toxicity compared with paclitaxel monotherapy in PROC patients....
Although paclitaxel is a promising first-line chemotherapeutic drug for ovarian cancer, acquired resistance to paclitaxel is one of the leading causes of treatment failure, limiting its clinical appli...
Human ovarian cancer cell lines MES and its PTX-resistant counterpart MES-TP cell lines were used and were treated with Asparagus officinalis and paclitaxel alone as well as in combination. Cell proli...
In this study, we found that Asparagus officinalis combined with low-dose paclitaxel synergistically inhibited cell proliferation, induced cellular stress and apoptosis and reduced cell invasion in pa...
These findings suggest that the combination of Asparagus officinalis and paclitaxel have potential clinical implications for development as a novel ovarian cancer treatment strategy....
This study aimed to assess the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metast...
Between October 2020 and March 2022, consecutive patients with diagnosed with metastatic or recurrent cervical cancer were retrospectively recruited in our hospital. Fifty-four patients were treated w...
The nab-paclitaxel group showed a higher ORR than the paclitaxel group both in the raw dataset (72.2% vs. 45.8%; P = 0.025) and matched dataset (81.1% vs. 47.6%; P = 0.008). The median PFS was signifi...
Compared with paclitaxel plus platinum, nab-paclitaxel plus platinum may be an effective and tolerable option as first-line therapy for patients with metastatic or recurrent cervical cancer....
The facile availability of nanoformulations with enhanced antitumor performance remains a big challenge. Herein, we synthesize paclitaxel prodrugs with amphiphilic structures and robust assembling abi...